Swiss pharmaceutical company Novartis will buy Avidity Biosciences for $12 billion
Swiss drugmaker Novartis said on Sunday it has agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare muscle disorders. Under the terms of the deal, Avidity shareholders will receive $72 per share in cash, representing a 46% premium…